4.7 Review

TWEAK and Fn14: New molecular targets for cancer therapy?

Journal

CANCER LETTERS
Volume 235, Issue 1, Pages 11-17

Publisher

ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2005.03.048

Keywords

TNF; TWEAK; Fn14; cancer tumor; endothelial cell; angiogenesis

Categories

Funding

  1. NHLBI NIH HHS [HL-39727] Funding Source: Medline
  2. NINDS NIH HHS [NS-42262] Funding Source: Medline

Ask authors/readers for more resources

Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) is a member of the tumor necrosis factor (TNF) superfamily of structurally related cytokines. Full-length, membrane-anchored TWEAK can be found on the surface of many cell types and a smaller, biologically active form, generated via proteolytic processing, has also been detected in the extracellular milieu. TWEAK acts via binding to a recently identified TNF receptor superfamily member named fibroblast growth factor-inducible 14 (Fn14). It has been demonstrated that TWEAK binding to the Fn14 receptor, or constitutive Fn14 overexpression, activates the nuclear factor-KB signaling pathway, which is known to play an important role in immune and inflammatory processes, oncogenesis, and cancer therapy resistance. In this article, we review recent studies indicating that TWEAK and Fn14 may be potential regulators of human tumorigenesis. (c) 2005 Elsevier Ireland Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available